SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DE |
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
2.1B EUR |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
204.9B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
153.2B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
46.3T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
35.4B CHF |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
280B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
36.9B USD |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
31.9B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
28.3B USD |
Loading...
|
|
| US |
|
Waters Corp
NYSE:WAT
|
22.8B USD |
Loading...
|
Market Distribution
| Min | -61 459.6% |
| 30th Percentile | 0.7% |
| Median | 4.5% |
| 70th Percentile | 9.8% |
| Max | 94 540% |
Other Profitability Ratios
SCHOTT Pharma AG & Co KgaA
Glance View
SCHOTT Pharma AG & Co KgaA, carved from the renowned SCHOTT AG, stands as a beacon in the pharmaceutical packaging industry. With roots deeply embedded in scientific glass manufacturing, SCHOTT Pharma specializes in providing sophisticated solutions for the containment and delivery of medicines. Their core expertise revolves around the development and production of high-quality glass and polymer products, including pre-fillable syringes, vials, and cartridges. These products are meticulously crafted to meet the stringent safety and quality demands of the healthcare sector, ensuring optimal preservation and delivery of pharmaceutical substances. The company leverages its profound understanding of material science, coupled with a focus on innovation, to offer tailored solutions to pharmaceutical companies across the globe. SCHOTT Pharma's business model thrives on collaboration and partnership with its clients, ensuring their specific needs are met with precision. The firm earns its revenue by forging long-term relationships with leading pharmaceutical players, supplying them with specialized containers designed to enhance drug stability and extend shelf life. This relationship is symbiotic, as SCHOTT Pharma not only provides the physical packaging but also lends its expertise in regulatory compliance and product testing, thereby positioning itself as a crucial contributor to its clients' overall success. By investing deeply in research and development, SCHOTT Pharma continues to innovate, maintaining its competitive edge and ensuring consistent demand for its high-performance pharmaceutical packaging solutions.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for SCHOTT Pharma AG & Co KgaA is 19%, which is above its 3-year median of 18.9%.
Over the last 2 years, SCHOTT Pharma AG & Co KgaA’s Operating Margin has decreased from 19% to 19%. During this period, it reached a low of 16.8% on Dec 31, 2024 and a high of 20.2% on Dec 31, 2023.